Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Amurubicin in Refractory SCLC
NCT03253068Phase 2Unknown
- Sponsor
- Wakayama Medical University
- Start
- Aug 2017
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in small cell lung cancer (SCLC), sponsored by Wakayama Medical University. Primary endpoint: Overall Response Rate at 6 months. Status: unknown.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03253068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03253068.